Moreover, the mean age at cancer diagnosis is much higher in MSH6 mutation carriers (about 56 y.o. for CRC and 55 y.o. for endometrial cancer) compared to MLH1, MSH2, and PMS2 mutation carriers [119,120,247]. This evidence concerns the gene MSH2 and cancer.